Yahoo Finance28d
CSL Vifor and Travere Therapeutics Announce Swissmedic approval of FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
ST. GALLEN, Switzerland and SAN DIEGO, Oct. 17, 2024 /PRNewswire/ -- CSL Vifor and Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that Swissmedic has granted temporary marketing ...
pharmaphorum2y
Australia's CSL makes $11.7bn bid for Swiss pharma Vifor
CSL's offer comes as Vifor has been hitting the acquisition trail itself, with deals to acquire Spain's Sanifit and fellow Swiss biotech Inositec for a combined value of around $254 million ...
PR Newswire28d
CSL Vifor and Travere Therapeutics Announce Swissmedic approval of FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
"Together with our partner, CSL Vifor, we look forward to people living with IgAN in Switzerland gaining access to this important medicine." Swissmedic approval was supported by results from the ...
Yahoo Finance28d
CSL Vifor and Travere Therapeutics Announce Swissmedic approval of FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
CSL Vifor Logo (PRNewsfoto/Vifor International AG (CSL Vifor)) "Swissmedic approval further demonstrates our promise to deliver transformational medicines for patients with serious diseases in our ...
Mena FN28d
CSL Vifor And Travere Therapeutics Announce Swissmedic Approval Of FILSPARI® (Sparsentan) For The Treatment Of Iga Nephropathy
CSL Vifor has been granted exclusive commercialization rights for FILSPARI in Europe, Australia and New Zealand.
Business Insider28d
Travere Therapeutics and CSL Vifor Announce Swissmedic Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy
SAN DIEGO, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (Nasdaq: TVTX) and CSL Vifor today announced that Swissmedic has granted temporary marketing authorization for FILSPARI for ...
Yahoo Finance28d
CSL Vifor and Travere Therapeutics Announce Swissmedic approval of FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
CSL Vifor Logo "Swissmedic approval further demonstrates our promise to deliver transformational medicines for patients with serious diseases in our areas of focus," said Emmanuelle Lecomte Brisset, ...